PortfoliosLab logo

Adaptimmune Therapeutics plc (ADAP)

Equity · Currency in USD · Last updated Mar 21, 2023

Share Price Chart

Loading data...


The chart shows the growth of $10,000 invested in Adaptimmune Therapeutics plc in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $681 for a total return of roughly -93.19%. All prices are adjusted for splits and dividends.

ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ADAP

Adaptimmune Therapeutics plc

Popular comparisons: ADAP vs. SCHD


Adaptimmune Therapeutics plc had a return of -25.34% year-to-date (YTD) and -50.00% in the last 12 months. Over the past 10 years, Adaptimmune Therapeutics plc had an annualized return of -28.95%, while the S&P 500 had an annualized return of 8.51%, indicating that Adaptimmune Therapeutics plc did not perform as well as the benchmark.

1 month-36.26%-3.13%
6 months-28.76%2.02%
1 year-50.00%-11.46%
5 years (annualized)-36.31%7.79%
10 years (annualized)-28.95%8.51%

Monthly Returns Heatmap


Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Adaptimmune Therapeutics plc Sharpe ratio is -0.53. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Dividend History

Adaptimmune Therapeutics plc doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.

ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Adaptimmune Therapeutics plc. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Adaptimmune Therapeutics plc is 96.57%, recorded on Nov 15, 2019. The portfolio has not recovered from it yet.



To Bottom


To Recover



-96.57%Jun 17, 20151114Nov 15, 2019
-14.05%May 8, 201517Jun 2, 20157Jun 11, 201524

Volatility Chart

Current Adaptimmune Therapeutics plc volatility is 66.59%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.

ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)